PubMed:9872676 JSONTXT

{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":69},"obj":"Sentence"},{"id":"T2","span":{"begin":70,"end":134},"obj":"Sentence"},{"id":"T3","span":{"begin":135,"end":281},"obj":"Sentence"},{"id":"T4","span":{"begin":282,"end":425},"obj":"Sentence"},{"id":"T5","span":{"begin":426,"end":591},"obj":"Sentence"},{"id":"T6","span":{"begin":592,"end":733},"obj":"Sentence"},{"id":"T7","span":{"begin":734,"end":922},"obj":"Sentence"},{"id":"T8","span":{"begin":923,"end":965},"obj":"Sentence"},{"id":"T9","span":{"begin":966,"end":1060},"obj":"Sentence"},{"id":"T10","span":{"begin":1061,"end":1239},"obj":"Sentence"},{"id":"T11","span":{"begin":1240,"end":1363},"obj":"Sentence"},{"id":"T12","span":{"begin":1364,"end":1455},"obj":"Sentence"},{"id":"T13","span":{"begin":1456,"end":1574},"obj":"Sentence"},{"id":"T14","span":{"begin":1575,"end":1695},"obj":"Sentence"},{"id":"T15","span":{"begin":1696,"end":1833},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":69},"obj":"Sentence"},{"id":"T2","span":{"begin":70,"end":134},"obj":"Sentence"},{"id":"T3","span":{"begin":135,"end":281},"obj":"Sentence"},{"id":"T4","span":{"begin":282,"end":425},"obj":"Sentence"},{"id":"T5","span":{"begin":426,"end":591},"obj":"Sentence"},{"id":"T6","span":{"begin":592,"end":733},"obj":"Sentence"},{"id":"T7","span":{"begin":734,"end":922},"obj":"Sentence"},{"id":"T8","span":{"begin":923,"end":965},"obj":"Sentence"},{"id":"T9","span":{"begin":966,"end":1060},"obj":"Sentence"},{"id":"T10","span":{"begin":1061,"end":1239},"obj":"Sentence"},{"id":"T11","span":{"begin":1240,"end":1363},"obj":"Sentence"},{"id":"T12","span":{"begin":1364,"end":1455},"obj":"Sentence"},{"id":"T13","span":{"begin":1456,"end":1574},"obj":"Sentence"},{"id":"T14","span":{"begin":1575,"end":1695},"obj":"Sentence"},{"id":"T15","span":{"begin":1696,"end":1833},"obj":"Sentence"}],"text":"Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes.\nInterleukin-10 (IL-10) protects animals from lethal endotoxemia. This beneficial effect is mediated, in part, by inhibition of inflammatory cytokine production, including tumor necrosis factor-alpha (TNF-alpha). Evidence suggests that IL-10 may inhibit activation of the transcription factor nuclear factor-kappaB (NF-kappaB) through an unknown mechanism. NF-kappaB activation in response to inflammatory signals is dependent upon degradation of its associated inhibitory peptide, inhibitory kappaB-alpha (IkappaB-alpha). We hypothesized that IL-10 prevents human monocyte NF-kappaB activation and resultant TNF-alpha production by stabilization of IkappaB-alpha. The purpose of this study was to determine the effect of IL-10 on lipopolysaccharide (LPS)-induced human monocyte TNF-alpha production, NF-kappaB activation, and IkappaB-alpha degradation. Monocytes were isolated from human donors. Cells were stimulated with endotoxin (LPS, 100 ng/mL) with and without human IL-10 (10 ng/mL). Following stimulation, TNF-alpha was measured in cell supernatants by ELISA, NF-kappaB activity by electrophoretic mobility shift assay, and IkappaB-alpha levels by Western blot. We observed that after LPS stimulation of human monocytes, TNF-alpha increased to 798+/-67 pg/mL (p \u003c .001 versus control). IL-10 attenuated LPS-stimulated TNF-alpha production (297+/-54; p \u003c .001 versus LPS alone). After LPS stimulation in human monocytes, IkappaB-alpha protein levels decreased, and NF-kappaB DNA binding increased. IL-10 pretreatment prevented LPS-induced decreases in IkappaB-alpha protein levels and attenuated NF-kappaB DNA binding. IL-10 appears to prevent activation of NF-kappaB by preserving IkappaB-alpha protein levels, leading to a reduction in TNF-alpha release."}

{"project":"jnlpba-st-training","denotations":[{"id":"T1","span":{"begin":0,"end":14},"obj":"protein"},{"id":"T2","span":{"begin":37,"end":49},"obj":"protein"},{"id":"T3","span":{"begin":53,"end":68},"obj":"cell_type"},{"id":"T4","span":{"begin":70,"end":84},"obj":"protein"},{"id":"T5","span":{"begin":86,"end":91},"obj":"protein"},{"id":"T6","span":{"begin":197,"end":218},"obj":"protein"},{"id":"T7","span":{"begin":241,"end":268},"obj":"protein"},{"id":"T8","span":{"begin":270,"end":279},"obj":"protein"},{"id":"T9","span":{"begin":305,"end":310},"obj":"protein"},{"id":"T10","span":{"begin":341,"end":361},"obj":"protein"},{"id":"T11","span":{"begin":362,"end":383},"obj":"protein"},{"id":"T12","span":{"begin":385,"end":394},"obj":"protein"},{"id":"T13","span":{"begin":426,"end":435},"obj":"protein"},{"id":"T14","span":{"begin":551,"end":574},"obj":"protein"},{"id":"T15","span":{"begin":576,"end":589},"obj":"protein"},{"id":"T16","span":{"begin":613,"end":618},"obj":"protein"},{"id":"T17","span":{"begin":643,"end":652},"obj":"protein"},{"id":"T18","span":{"begin":678,"end":687},"obj":"protein"},{"id":"T19","span":{"begin":719,"end":732},"obj":"protein"},{"id":"T20","span":{"begin":791,"end":796},"obj":"protein"},{"id":"T21","span":{"begin":848,"end":857},"obj":"protein"},{"id":"T22","span":{"begin":870,"end":879},"obj":"protein"},{"id":"T23","span":{"begin":896,"end":909},"obj":"protein"},{"id":"T24","span":{"begin":993,"end":1002},"obj":"protein"},{"id":"T25","span":{"begin":1043,"end":1048},"obj":"protein"},{"id":"T26","span":{"begin":1084,"end":1093},"obj":"protein"},{"id":"T27","span":{"begin":1138,"end":1147},"obj":"protein"},{"id":"T28","span":{"begin":1202,"end":1215},"obj":"protein"},{"id":"T29","span":{"begin":1282,"end":1297},"obj":"cell_type"},{"id":"T30","span":{"begin":1299,"end":1308},"obj":"protein"},{"id":"T31","span":{"begin":1364,"end":1369},"obj":"protein"},{"id":"T32","span":{"begin":1396,"end":1405},"obj":"protein"},{"id":"T33","span":{"begin":1481,"end":1496},"obj":"cell_type"},{"id":"T34","span":{"begin":1498,"end":1511},"obj":"protein"},{"id":"T35","span":{"begin":1542,"end":1551},"obj":"protein"},{"id":"T36","span":{"begin":1575,"end":1580},"obj":"protein"},{"id":"T37","span":{"begin":1629,"end":1642},"obj":"protein"},{"id":"T38","span":{"begin":1673,"end":1682},"obj":"protein"},{"id":"T39","span":{"begin":1696,"end":1701},"obj":"protein"},{"id":"T40","span":{"begin":1735,"end":1744},"obj":"protein"},{"id":"T41","span":{"begin":1759,"end":1772},"obj":"protein"},{"id":"T42","span":{"begin":1815,"end":1824},"obj":"protein"}],"text":"Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes.\nInterleukin-10 (IL-10) protects animals from lethal endotoxemia. This beneficial effect is mediated, in part, by inhibition of inflammatory cytokine production, including tumor necrosis factor-alpha (TNF-alpha). Evidence suggests that IL-10 may inhibit activation of the transcription factor nuclear factor-kappaB (NF-kappaB) through an unknown mechanism. NF-kappaB activation in response to inflammatory signals is dependent upon degradation of its associated inhibitory peptide, inhibitory kappaB-alpha (IkappaB-alpha). We hypothesized that IL-10 prevents human monocyte NF-kappaB activation and resultant TNF-alpha production by stabilization of IkappaB-alpha. The purpose of this study was to determine the effect of IL-10 on lipopolysaccharide (LPS)-induced human monocyte TNF-alpha production, NF-kappaB activation, and IkappaB-alpha degradation. Monocytes were isolated from human donors. Cells were stimulated with endotoxin (LPS, 100 ng/mL) with and without human IL-10 (10 ng/mL). Following stimulation, TNF-alpha was measured in cell supernatants by ELISA, NF-kappaB activity by electrophoretic mobility shift assay, and IkappaB-alpha levels by Western blot. We observed that after LPS stimulation of human monocytes, TNF-alpha increased to 798+/-67 pg/mL (p \u003c .001 versus control). IL-10 attenuated LPS-stimulated TNF-alpha production (297+/-54; p \u003c .001 versus LPS alone). After LPS stimulation in human monocytes, IkappaB-alpha protein levels decreased, and NF-kappaB DNA binding increased. IL-10 pretreatment prevented LPS-induced decreases in IkappaB-alpha protein levels and attenuated NF-kappaB DNA binding. IL-10 appears to prevent activation of NF-kappaB by preserving IkappaB-alpha protein levels, leading to a reduction in TNF-alpha release."}

{"project":"genia-medco-coref","denotations":[{"id":"C1","span":{"begin":0,"end":14},"obj":"NP"},{"id":"C2","span":{"begin":26,"end":49},"obj":"NP"},{"id":"C3","span":{"begin":53,"end":68},"obj":"NP"},{"id":"C4","span":{"begin":70,"end":92},"obj":"NP"},{"id":"C5","span":{"begin":241,"end":280},"obj":"NP"},{"id":"C6","span":{"begin":305,"end":310},"obj":"NP"},{"id":"C7","span":{"begin":323,"end":395},"obj":"NP"},{"id":"C8","span":{"begin":426,"end":446},"obj":"NP"},{"id":"C10","span":{"begin":516,"end":519},"obj":"NP"},{"id":"C9","span":{"begin":516,"end":549},"obj":"NP"},{"id":"C11","span":{"begin":551,"end":590},"obj":"NP"},{"id":"C12","span":{"begin":613,"end":618},"obj":"NP"},{"id":"C13","span":{"begin":628,"end":663},"obj":"NP"},{"id":"C14","span":{"begin":719,"end":732},"obj":"NP"},{"id":"C15","span":{"begin":791,"end":796},"obj":"NP"},{"id":"C16","span":{"begin":800,"end":868},"obj":"NP"},{"id":"C17","span":{"begin":870,"end":890},"obj":"NP"},{"id":"C18","span":{"begin":923,"end":932},"obj":"NP"},{"id":"C19","span":{"begin":1037,"end":1048},"obj":"NP"},{"id":"C20","span":{"begin":1084,"end":1093},"obj":"NP"},{"id":"C21","span":{"begin":1282,"end":1297},"obj":"NP"},{"id":"C22","span":{"begin":1299,"end":1308},"obj":"NP"},{"id":"C23","span":{"begin":1364,"end":1369},"obj":"NP"},{"id":"C24","span":{"begin":1381,"end":1416},"obj":"NP"},{"id":"C25","span":{"begin":1481,"end":1496},"obj":"NP"},{"id":"C26","span":{"begin":1498,"end":1526},"obj":"NP"},{"id":"C27","span":{"begin":1542,"end":1563},"obj":"NP"},{"id":"C28","span":{"begin":1629,"end":1657},"obj":"NP"},{"id":"C29","span":{"begin":1673,"end":1694},"obj":"NP"},{"id":"C30","span":{"begin":1696,"end":1701},"obj":"NP"},{"id":"C31","span":{"begin":1721,"end":1744},"obj":"NP"},{"id":"C32","span":{"begin":1759,"end":1787},"obj":"NP"}],"relations":[{"id":"R1","pred":"coref-ident","subj":"C4","obj":"C1"},{"id":"R2","pred":"coref-ident","subj":"C6","obj":"C4"},{"id":"R3","pred":"coref-pron","subj":"C10","obj":"C8"},{"id":"R4","pred":"coref-ident","subj":"C9","obj":"C2"},{"id":"R5","pred":"coref-appos","subj":"C11","obj":"C9"},{"id":"R6","pred":"coref-ident","subj":"C12","obj":"C6"},{"id":"R7","pred":"coref-ident","subj":"C13","obj":"C7"},{"id":"R8","pred":"coref-ident","subj":"C14","obj":"C11"},{"id":"R9","pred":"coref-ident","subj":"C15","obj":"C12"},{"id":"R10","pred":"coref-ident","subj":"C17","obj":"C13"},{"id":"R11","pred":"coref-ident","subj":"C18","obj":"C3"},{"id":"R12","pred":"coref-ident","subj":"C19","obj":"C15"},{"id":"R13","pred":"coref-ident","subj":"C20","obj":"C5"},{"id":"R14","pred":"coref-ident","subj":"C21","obj":"C18"},{"id":"R15","pred":"coref-ident","subj":"C22","obj":"C20"},{"id":"R16","pred":"coref-ident","subj":"C23","obj":"C19"},{"id":"R17","pred":"coref-ident","subj":"C24","obj":"C16"},{"id":"R18","pred":"coref-ident","subj":"C25","obj":"C21"},{"id":"R19","pred":"coref-ident","subj":"C28","obj":"C26"},{"id":"R20","pred":"coref-ident","subj":"C29","obj":"C27"},{"id":"R21","pred":"coref-ident","subj":"C30","obj":"C23"},{"id":"R22","pred":"coref-ident","subj":"C31","obj":"C17"},{"id":"R23","pred":"coref-ident","subj":"C32","obj":"C28"}],"text":"Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes.\nInterleukin-10 (IL-10) protects animals from lethal endotoxemia. This beneficial effect is mediated, in part, by inhibition of inflammatory cytokine production, including tumor necrosis factor-alpha (TNF-alpha). Evidence suggests that IL-10 may inhibit activation of the transcription factor nuclear factor-kappaB (NF-kappaB) through an unknown mechanism. NF-kappaB activation in response to inflammatory signals is dependent upon degradation of its associated inhibitory peptide, inhibitory kappaB-alpha (IkappaB-alpha). We hypothesized that IL-10 prevents human monocyte NF-kappaB activation and resultant TNF-alpha production by stabilization of IkappaB-alpha. The purpose of this study was to determine the effect of IL-10 on lipopolysaccharide (LPS)-induced human monocyte TNF-alpha production, NF-kappaB activation, and IkappaB-alpha degradation. Monocytes were isolated from human donors. Cells were stimulated with endotoxin (LPS, 100 ng/mL) with and without human IL-10 (10 ng/mL). Following stimulation, TNF-alpha was measured in cell supernatants by ELISA, NF-kappaB activity by electrophoretic mobility shift assay, and IkappaB-alpha levels by Western blot. We observed that after LPS stimulation of human monocytes, TNF-alpha increased to 798+/-67 pg/mL (p \u003c .001 versus control). IL-10 attenuated LPS-stimulated TNF-alpha production (297+/-54; p \u003c .001 versus LPS alone). After LPS stimulation in human monocytes, IkappaB-alpha protein levels decreased, and NF-kappaB DNA binding increased. IL-10 pretreatment prevented LPS-induced decreases in IkappaB-alpha protein levels and attenuated NF-kappaB DNA binding. IL-10 appears to prevent activation of NF-kappaB by preserving IkappaB-alpha protein levels, leading to a reduction in TNF-alpha release."}

{"project":"pubmed-sentences-benchmark","denotations":[{"id":"S1","span":{"begin":0,"end":69},"obj":"Sentence"},{"id":"S2","span":{"begin":70,"end":134},"obj":"Sentence"},{"id":"S3","span":{"begin":135,"end":281},"obj":"Sentence"},{"id":"S4","span":{"begin":282,"end":425},"obj":"Sentence"},{"id":"S5","span":{"begin":426,"end":591},"obj":"Sentence"},{"id":"S6","span":{"begin":592,"end":733},"obj":"Sentence"},{"id":"S7","span":{"begin":734,"end":922},"obj":"Sentence"},{"id":"S8","span":{"begin":923,"end":965},"obj":"Sentence"},{"id":"S9","span":{"begin":966,"end":1060},"obj":"Sentence"},{"id":"S10","span":{"begin":1061,"end":1239},"obj":"Sentence"},{"id":"S11","span":{"begin":1240,"end":1363},"obj":"Sentence"},{"id":"S12","span":{"begin":1364,"end":1455},"obj":"Sentence"},{"id":"S13","span":{"begin":1456,"end":1574},"obj":"Sentence"},{"id":"S14","span":{"begin":1575,"end":1695},"obj":"Sentence"},{"id":"S15","span":{"begin":1696,"end":1833},"obj":"Sentence"}],"text":"Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes.\nInterleukin-10 (IL-10) protects animals from lethal endotoxemia. This beneficial effect is mediated, in part, by inhibition of inflammatory cytokine production, including tumor necrosis factor-alpha (TNF-alpha). Evidence suggests that IL-10 may inhibit activation of the transcription factor nuclear factor-kappaB (NF-kappaB) through an unknown mechanism. NF-kappaB activation in response to inflammatory signals is dependent upon degradation of its associated inhibitory peptide, inhibitory kappaB-alpha (IkappaB-alpha). We hypothesized that IL-10 prevents human monocyte NF-kappaB activation and resultant TNF-alpha production by stabilization of IkappaB-alpha. The purpose of this study was to determine the effect of IL-10 on lipopolysaccharide (LPS)-induced human monocyte TNF-alpha production, NF-kappaB activation, and IkappaB-alpha degradation. Monocytes were isolated from human donors. Cells were stimulated with endotoxin (LPS, 100 ng/mL) with and without human IL-10 (10 ng/mL). Following stimulation, TNF-alpha was measured in cell supernatants by ELISA, NF-kappaB activity by electrophoretic mobility shift assay, and IkappaB-alpha levels by Western blot. We observed that after LPS stimulation of human monocytes, TNF-alpha increased to 798+/-67 pg/mL (p \u003c .001 versus control). IL-10 attenuated LPS-stimulated TNF-alpha production (297+/-54; p \u003c .001 versus LPS alone). After LPS stimulation in human monocytes, IkappaB-alpha protein levels decreased, and NF-kappaB DNA binding increased. IL-10 pretreatment prevented LPS-induced decreases in IkappaB-alpha protein levels and attenuated NF-kappaB DNA binding. IL-10 appears to prevent activation of NF-kappaB by preserving IkappaB-alpha protein levels, leading to a reduction in TNF-alpha release."}

{"project":"GENIAcorpus","denotations":[{"id":"T1","span":{"begin":0,"end":14},"obj":"protein_molecule"},{"id":"T2","span":{"begin":37,"end":49},"obj":"protein_molecule"},{"id":"T3","span":{"begin":53,"end":68},"obj":"cell_type"},{"id":"T4","span":{"begin":70,"end":84},"obj":"protein_molecule"},{"id":"T5","span":{"begin":86,"end":91},"obj":"protein_molecule"},{"id":"T6","span":{"begin":115,"end":133},"obj":"other_name"},{"id":"T7","span":{"begin":197,"end":218},"obj":"protein_family_or_group"},{"id":"T8","span":{"begin":241,"end":268},"obj":"protein_molecule"},{"id":"T9","span":{"begin":270,"end":279},"obj":"protein_molecule"},{"id":"T10","span":{"begin":305,"end":310},"obj":"protein_molecule"},{"id":"T11","span":{"begin":341,"end":361},"obj":"protein_family_or_group"},{"id":"T12","span":{"begin":362,"end":383},"obj":"protein_molecule"},{"id":"T13","span":{"begin":385,"end":394},"obj":"protein_complex"},{"id":"T14","span":{"begin":426,"end":435},"obj":"protein_complex"},{"id":"T15","span":{"begin":462,"end":482},"obj":"other_name"},{"id":"T16","span":{"begin":531,"end":549},"obj":"peptide"},{"id":"T17","span":{"begin":551,"end":574},"obj":"protein_molecule"},{"id":"T18","span":{"begin":576,"end":589},"obj":"protein_molecule"},{"id":"T19","span":{"begin":613,"end":618},"obj":"protein_molecule"},{"id":"T20","span":{"begin":628,"end":642},"obj":"other_name"},{"id":"T21","span":{"begin":643,"end":652},"obj":"protein_complex"},{"id":"T22","span":{"begin":678,"end":687},"obj":"protein_molecule"},{"id":"T23","span":{"begin":719,"end":732},"obj":"protein_molecule"},{"id":"T24","span":{"begin":791,"end":796},"obj":"protein_molecule"},{"id":"T25","span":{"begin":819,"end":847},"obj":"other_name"},{"id":"T26","span":{"begin":848,"end":857},"obj":"protein_molecule"},{"id":"T27","span":{"begin":870,"end":879},"obj":"protein_complex"},{"id":"T28","span":{"begin":896,"end":909},"obj":"protein_molecule"},{"id":"T29","span":{"begin":952,"end":964},"obj":"multi_cell"},{"id":"T30","span":{"begin":993,"end":1002},"obj":"protein_family_or_group"},{"id":"T31","span":{"begin":1004,"end":1007},"obj":"lipid"},{"id":"T32","span":{"begin":1043,"end":1048},"obj":"protein_molecule"},{"id":"T33","span":{"begin":1084,"end":1093},"obj":"protein_molecule"},{"id":"T34","span":{"begin":1131,"end":1136},"obj":"other_name"},{"id":"T35","span":{"begin":1138,"end":1147},"obj":"protein_complex"},{"id":"T36","span":{"begin":1160,"end":1196},"obj":"other_name"},{"id":"T37","span":{"begin":1202,"end":1215},"obj":"protein_molecule"},{"id":"T38","span":{"begin":1226,"end":1238},"obj":"other_name"},{"id":"T39","span":{"begin":1263,"end":1266},"obj":"lipid"},{"id":"T40","span":{"begin":1282,"end":1297},"obj":"cell_type"},{"id":"T41","span":{"begin":1299,"end":1308},"obj":"protein_molecule"},{"id":"T42","span":{"begin":1364,"end":1369},"obj":"protein_molecule"},{"id":"T43","span":{"begin":1381,"end":1384},"obj":"lipid"},{"id":"T44","span":{"begin":1396,"end":1405},"obj":"protein_molecule"},{"id":"T45","span":{"begin":1444,"end":1447},"obj":"lipid"},{"id":"T46","span":{"begin":1462,"end":1465},"obj":"lipid"},{"id":"T47","span":{"begin":1481,"end":1496},"obj":"cell_type"},{"id":"T48","span":{"begin":1498,"end":1511},"obj":"protein_molecule"},{"id":"T49","span":{"begin":1542,"end":1551},"obj":"protein_complex"},{"id":"T50","span":{"begin":1575,"end":1580},"obj":"protein_molecule"},{"id":"T51","span":{"begin":1604,"end":1607},"obj":"lipid"},{"id":"T52","span":{"begin":1629,"end":1642},"obj":"protein_molecule"},{"id":"T53","span":{"begin":1673,"end":1682},"obj":"protein_complex"},{"id":"T54","span":{"begin":1696,"end":1701},"obj":"protein_molecule"},{"id":"T55","span":{"begin":1735,"end":1744},"obj":"protein_complex"},{"id":"T56","span":{"begin":1759,"end":1772},"obj":"protein_molecule"},{"id":"T57","span":{"begin":1815,"end":1824},"obj":"protein_molecule"}],"text":"Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes.\nInterleukin-10 (IL-10) protects animals from lethal endotoxemia. This beneficial effect is mediated, in part, by inhibition of inflammatory cytokine production, including tumor necrosis factor-alpha (TNF-alpha). Evidence suggests that IL-10 may inhibit activation of the transcription factor nuclear factor-kappaB (NF-kappaB) through an unknown mechanism. NF-kappaB activation in response to inflammatory signals is dependent upon degradation of its associated inhibitory peptide, inhibitory kappaB-alpha (IkappaB-alpha). We hypothesized that IL-10 prevents human monocyte NF-kappaB activation and resultant TNF-alpha production by stabilization of IkappaB-alpha. The purpose of this study was to determine the effect of IL-10 on lipopolysaccharide (LPS)-induced human monocyte TNF-alpha production, NF-kappaB activation, and IkappaB-alpha degradation. Monocytes were isolated from human donors. Cells were stimulated with endotoxin (LPS, 100 ng/mL) with and without human IL-10 (10 ng/mL). Following stimulation, TNF-alpha was measured in cell supernatants by ELISA, NF-kappaB activity by electrophoretic mobility shift assay, and IkappaB-alpha levels by Western blot. We observed that after LPS stimulation of human monocytes, TNF-alpha increased to 798+/-67 pg/mL (p \u003c .001 versus control). IL-10 attenuated LPS-stimulated TNF-alpha production (297+/-54; p \u003c .001 versus LPS alone). After LPS stimulation in human monocytes, IkappaB-alpha protein levels decreased, and NF-kappaB DNA binding increased. IL-10 pretreatment prevented LPS-induced decreases in IkappaB-alpha protein levels and attenuated NF-kappaB DNA binding. IL-10 appears to prevent activation of NF-kappaB by preserving IkappaB-alpha protein levels, leading to a reduction in TNF-alpha release."}